Surrozen

Restoring Vision Through the Science of Renewal



March 2026

Legal Disclaimers

This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye disease, as well as the potential benefits of such product candidates), expectations regarding timing of an IND application and the Company’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates, and potential future drug candidates; Surrozen’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission ("SEC") under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this presentation. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. This presentation is not an offer to sell, a solicitation of an offer to buy or a recommendation to purchase any security, nor is it a solicitation of a proxy, consent or authorization with respect to any securities transaction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Designing Best-in-Disease Multi-Functional Antibodies for Retinal Vascular Disease

Clear Rationale for Combining Complementary MOAs

- Commercial: Market leader (Vabysmo) combines two targets
- Clinical: Compelling clinical benefit across studies and retinopathies for combining MOAs

Pursuing the Optimal Combinations

- Wnt: Genetic and clinical proof of concept related to retinal vessel function
- VEGF: Current drugs with the largest clinical benefit in retinopathies
- IL-6: Emerging clinical evidence of importance in DME and uveitis

Leaders in Wnt Targeting

- Innovators in modulating Wnt signaling with multi-specific antibodies (16 publications)
- Broad and growing IP portfolio covering novel antibody formats, mechanisms, and disease targets

Multiple Candidates For Best Anatomic Outcomes

- Two lead candidates designed to advance the field towards combination therapy
- First antibodies to combine Wnt and anti-VEGF and/or anti-IL6 for best retinal drying
- Preclinical results demonstrate superiority to standard of care and MOA synergy
- IND submission in second half of 2026

Retinal Vascular Diseases (DME, wet AMD) are Large and Growing Markets with Significant Unmet Need

	Retinal Vascular Diseases
US Prevalence[1]	2.3M
Global Prevalence	>40M[2,3]
Anti-VEGF Market[4-6]	$13B in 2025 -> >$20B in 2030 CAGR: ~10%
Morbidity[7]	- DME patients incur healthcare costs 2-3x higher vs having diabetes alone[4] - AMD is major cause of sight loss in the population >65
Key Products[1]	Anti-VEGF therapies: Aflibercept, Ranibizumab, Faricimab
Key Unmet Needs[8]	Need for better drying agents Need for longer lasting therapies Need for new therapies beyond VEGF inhibition

Global Anti-VEGF Agents Ophthalmic Drug Market



Source: 1. Health Advances DME and wet AMD primary market research for Surrozen - Nov 2024; 2. Im et al, Survey of Ophthalmology, July-Aug 2022; 3. Wong et al, Lancet Global Health Feb 2014; 4. Surrozen estimates from range of research report analyses: Datamonitor – Anti-VEGF wet AMD Grandview Research – Global Ophthalmic Drugs Market Size Outlook 2024, Global Market Insights - Ophthalmic Anti-VEGF Therapeutics; 5. Roche 2025 Financial Report; 6. Regeneron 2025 10-K; 7. Choi et al, 2024 Oct 8:10:e56741 doi: 10.2196/56741; 8. ASRS PATS Survey 2025.

Vabysmo (VEGF + Ang2): Blueprint for VEGF Combinations

Multiple targets drive additional clinical benefit
Incremental drying leads to rapid adoption

Vabysmo Clinical Outcomes in DME



Global Vabysmo Revenue



Source: Vabysmo Website; Roche Financial Reports 2022 – 2025.

Evidence that Adding to VEGF Inhibition Confers Additive Clinical Benefit

Roche demonstrated IL-6 in combination with VEGF inhibition superior to VEGF alone

Consistent BCVA gains for combination throughout the study

Large increase in percent of patients achieving greatest visual acuity gains: 44.7% of patients receiving combination gained ≥15 BCVA letters vs 28.6% with VEGF alone

Roche pursuing IL6 x VEGF bi-specific

Ph II (BARDENAS): Anti-IL-6 (vamikibart) + anti-VEGF (ranibizumab) showed superior efficacy in DME



Source: Roche ASOPRS/AAO 2025 IR Event Presentation.



Wnt Signaling

A Key Regulator of Vascular Biology

Surrozen

Wnt is A Key Regulator of Retinal Vascular Function

A complementary mechanism to VEGF inhibition

- **Biology**: Wnt signaling is essential for maintaining retinal vascular integrity and barrier function
- **Genetic Validation**: Mutations in FZD4 mediated Wnt signaling cause Norrie disease and FEVR — both marked by severe vascular defects
- **Preclinical Evidence**: Wnt mimetics restore vascular integrity, reduce leakage, and regenerate vasculature in models of retinal injury
- **Clinical Evidence**: Proof of concept established in DME patients with outcomes comparable to anti-VEGF therapy

Oxygen Induced Retinopathy Model



Restoret (Wnt agonist) Ph1b/2a Study

- 26 patient DME study
- BCVA gain of ~11 letters at 12 weeks
- Mean reduction in excess retinal thickness of 80%

Source: Data on file; EyeBio Press Release, February 13, 2024.
***p<0.001, ****p<0.0001 v. vehicle. N = 3-4 mice per group.

Wnt Biology is Driving Strategic Investment

SURROZEN'S SZN-413 | 2022

- Potential best-in-class FZD4 /LRP bi-specific antibody for retinal diseases like neovascular AMD and DME
- Licensed to Boehringer Ingelheim in October 2022
- Surrozen is a first-mover, building on the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway
- Surrozen received $12.5M upfront; potential milestones of up to $586.5M; mid-single to low double-digit royalties
- License scope enables Surrozen to pursue additional next-generation FZD4 targeted antibodies on its own

Boehringer Ingelheim

MERCK | 2024

Merck acquired EyeBio in 2024 for **$1.3B for Restoret (EYE103, MK-3000)**

Ophthalmology

- Completed **acquisition of EyeBio**
- **Restoret™/MK-3000** is an investigational, potentially first-in-class tetravalent tri-specific **Wnt antibody** for treatment of **diabetic macular edema and neovascular age-related macular degeneration**



Roche | 2024

Roche acquired AntlerA Therapeutics in 2024 for **a library of anti-FZD/LRP drug candidates**



Source: Merck Press Release, July 12, 2024; Roche Pharma Day 2024 Presentation.

Surrozen Advantage: Defining the Next Era of Retinal Repair

Architects of Drugging the Pathway:

Built by the world's leading experts who discovered the Wnt pathway, its role in tissue restoration and ligand:receptor biology

Next Generation Multifunctional Biologics:

First-in-class multifunctional biologics which combine Wnt activation with modulation of other drivers of retinal disease (VEGF, IL-6)

Antibody Design Leadership:

Deep expertise in FZD/LRP signal modulation – multiple publications on optimizing antibody formats

Broad IP Portfolio:

Our leadership is protected by a robust patent estate, including 8 issued U.S. patents and over 25 pending families globally

Our Development Pipeline

Surrozen

SZN-413: First FZD4/LRP5 Antibody Targeting Wnt Activation

Wnt Pathway:
Distinct Mechanism of Vascular Repair

Novel mechanism for treatment of retinal vascular diseases that can directly reduce leakage and restore blood-retina barrier function

Multiple preclinical models of retinal injury demonstrated that SZN-413 rapidly reduces vascular leakage and avascular areas

Licensed to Boehringer Ingelheim
- $12.5M upfront
- Potential total milestones up to $586.5M
- Mid-single to low double-digit royalties

Clustering FZD4 and LRP5 receptors on retinal vascular endothelial cells via a multi-valent, bi-specific antibody activates the Wnt signal transduction cascade. Downstream biological effects in the eye include up-regulation of tight-junction proteins, reduction in vessel leakage and re-establishment of normal vessel architecture



Wnt activation

Oxygen Induced Retinopathy Model

SZN-413 demonstrated superiority of reduction in total avascular area as well as comparable reduction in neovascular tufts compared to aflibercept



***p<0.001, ****p<0.0001 v. vehicle. n = 3-4 mice per group.

Second Generation Multi-Functional Wnt Targeted Antibodies

Complementary mechanisms enable potential best-in-disease antibodies

SZN-8141 – WNT Activation + VEGF Inhibition

Wnt activation via FZD4/LRP5

- Potential for best-in-class Wnt activation
- Wnt activation upregulates tight junction proteins and restores blood retina barrier function

VEGF inhibition via VEGF decoy receptors

Aflibercept sequences - comparable VEGF-A/PlGF binding affinity

- Reduces neovascularization and vascular leakage



FZD4 IgG1/LRP5VHH/VEGF soluble decoy receptor

SZN-8141 Restores Retinal Vessel Architecture



Novel mechanism for treatment of retinal vascular diseases that can directly reduce leakage and eliminate pathologic leaky vessels

Oxygen Induced Retinopathy Model



Control SZN-8141



80% reduction in avascular area

****p<0.0001 v. negative control. N = 12-14 mice per group.

SZN-8141 VEGF Binding Domains Neutralize Pathologic VEGF-A



VEGF soluble decoy receptor domains bind soluble VEGF-A with comparable affinity and potency to aflibercept

In vitro assays demonstrate similar potency, affinity and binding to aflibercept

KDR/NFAT-RE HEK293 Cell Potency Assay



Binding Affinity to VEGF (Kd)

SZN-8141	Aflibercept
<1pM	<1pM

SZN-8141 Synergy Observed with Wnt and VEGF Dual Mechanism



OIR Model (Delayed)

Reduction of avascular area



Reduction of neovascularization



**p<0.01, ****p<0.0001 v. negative control; #p<0.05, ###p<0.001 v. anti-VEGF + FZD4 agonist; n=7 mice for negative control and n=15 mice for active treatment groups.

SZN-8143: Targeting IL-6 Could Provide Additional Clinical Benefit in UME and Other Retinal Vascular Diseases

SZN-8143 – WNT + VEGF + IL-6

Wnt activation via FZD4/LRP5 Fv:VHH

IL-6 inhibition via anti-IL-6 IgG

- Reduces vascular permeability and VEGF production

VEGF inhibition via VEGF decoy receptors



IL-6 IgG1/LRP5VHH/FZD4 Fv/VEGF soluble decoy receptor

Additional Fc engineering to reduce liabilities

Fc and FcRn mutations to eliminate effector function (LALAPG) and reduce systemic exposure (AAA)

Wnt Biology Supports Multiple Therapeutics Opportunities in Ophthalmology

Pipeline Wnt agonists show promising preclinical activity across multiple disease models

Fuchs' Endothelial Dystrophy Program

- Loss of corneal endothelial cells causes corneal swelling, haziness and vision loss, accompanied by ECM deposition ("guttata")
- Development stage candidate demonstrated preclinical evidence of:
  - Rapid and significant reduction in central corneal thickness
  - Rapid improvement in corneal clarity
  - Stimulates proliferation in human cornea cultures

Geographic Atrophy Program

- Advanced form of macular degeneration that leads to progressive loss of central vision due to the degeneration of retinal cells
- Candidate demonstrated preclinical evidence of:
  - Neuroprotection in acute injury and progressive degeneration models of photoreceptor damage
  - Stimulation of RPE proliferation and differentiation in vitro

Retinitis Pigmentosa Program

- A group of genetic retinal disorders leading to degeneration of photoreceptors
- Candidate demonstrated preclinical evidence of impact on muller glial cells and photoreceptors

Ophthalmology Franchise: Multiple Novel High Value Candidates

PROGRAM	INDICATION	RESEARCH	PRE-CLINICAL	PHASE 1
SZN-413* **FZD4**	Retinopathies			
SZN-8141 **FZD4, VEGF**	wet AMD, DME			
SZN-8143 **FZD4, VEGF, IL-6**	wet AMD, DME, UME			
Research	Ocular disease			



Glossary: FZD - frizzled; VEGF - Vascular Endothelial Growth Factor; IL-6 – interleukin-6; AMD - Age-related Macular Degeneration; DME – Diabetic Macular Edema; UME – Uveitic Macular Edema

*Licensed to Boehringer Ingelheim.

Surrozen

Thank You

www.surrozen.com



Glossary

AMD	Age-related macular degeneration	**Lrp**	Lipoprotein receptor-related protein
DME	Diabetic macular edema	**POC**	Proof-of-concept
ECM	Extracellular matrix	**OIR**	Oxygen induced retinopathy
FEVR	Familial exudative vitreoretinopathy	**RPE**	Retinal pigment epithelium
FZD	Frizzled	**UME**	Uveitic macular edema
IND	Investigational new drug	**VEGF/R**	Vascular endothelial growth factor/receptors
IL-6	Interleukin 6	**Wnt**	Wingless-related integration site